Search

Displaying results 9811 - 9820 of 10000 in total
  1. Drug

    Epothilone D

    go.drugbank.com/drugs/DB01873
    Investigational

  2. Drug

    RPI-78M

    go.drugbank.com/drugs/DB05740
    Experimental

    RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).

  3. Drug

    AT-7519

    go.drugbank.com/drugs/DB08142
    Investigational

    AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression. It is developed by Astex for the treatment of solid tumours and haematological malignancies.

    Synonyms: 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide
  4. Drug

    NF-kappaB Decoy

    go.drugbank.com/drugs/DB05559
    Investigational

  5. Drug

    Cefilavancin

    go.drugbank.com/drugs/DB05735
    Investigational

    Cefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that exhibits substantially greater activity than its component parts against Gram-positive bacteria.

  6. Drug

    Facinicline

    go.drugbank.com/drugs/DB05586
    Investigational

  7. Drug

    Talotrexin

    go.drugbank.com/drugs/DB06178
    Investigational

  8. Drug

    Technetium Tc-99m arcitumomab

    go.drugbank.com/drugs/DB00113
    Experimental

    Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen (CEA) covalently labeled with Technitium 99. The molecule has a molecular weight of ~54,000 Daltons.

  9. Drug

    Nimorazole

    go.drugbank.com/drugs/DB12172
    Investigational

    Nimorazole has been used in trials studying the treatment of Hypoxia, Radiotherapy, Hypoxic Modification, Gene Profile, Gene Signature, and Head and Neck Squamous Cell Carcinoma, among others.

  10. Drug

    Idasanutlin

    go.drugbank.com/drugs/DB12325
    Investigational

    Idasanutlin has been used in trials studying the treatment of Neoplasms, Non-Hodgkin's Lymphoma, Leukemia, Myeloid, Acute, Recurrent Plasma Cell Myeloma, and Neoplasms, Leukemia, Acute Myeloid Leukemia